Bibliographies thématiques / Vulvar, cancer, paclitaxel

Sommaire

  1. Articles de revues
  2. Thèses

Littérature scientifique sur le sujet « Vulvar, cancer, paclitaxel »

Auteur : Grafiati
Publié le 9 mars 2023
Mis à jour le 10 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Vulvar, cancer, paclitaxel ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Vulvar, cancer, paclitaxel"

1

Musella, Angela, Claudia Marchetti, Laura Salerno, Laura Vertechy, Roberta Iadarola, Irene Pecorella et Pierluigi Benedetti Panici. « An Unexpected Complete Remission of Advanced Intestinal-Type Vulvar Adenocarcinoma after Neoadjuvant Chemotherapy : A Case Report and a Literature Review ». Case Reports in Obstetrics and Gynecology 2013 (2013) : 1–5. http://dx.doi.org/10.1155/2013/427141.

Texte intégral
Résumé :
Vulvar cancer represents approximately 3%–5% of all gynecological malignancies. Squamous cell carcinoma is the most frequent histotype, whereas melanomas, adenocarcinomas, basal cell carcinomas, and sarcomas are much less common. Intestinal-type adenocarcinoma is a rare variant of vulvar carcinoma with only few cases found in the literature. The origin of this neoplasia is still much debated, but the most reliable hypothesis is the origin from cloacal remnants that may persist in the adult in different organs. Because of its extremely low incidence, the optimal management of this kind of vulvar cancer is still debated. We report the case of a woman affected by advanced intestinal-type vulvar adenocarcinoma, who achieved a complete clinical and pathological response after neoadjuvant chemotherapeutic treatment with platinum and paclitaxel.
Styles APA, Harvard, Vancouver, ISO, etc.
2

Jaakkola, Misa, Virpi Rantanen, Seija Grénman, Jarmo Kulmala et Reidar Grénman. « In vitro concurrent paclitaxel and radiation of four vulvar squamous cell carcinoma cell lines ». Cancer 77, no 9 (1 mai 1996) : 1940–46. http://dx.doi.org/10.1002/(sici)1097-0142(19960501)77:9<1940 ::aid-cncr26>3.0.co;2-z.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
3

Han, Sileny N., Ignace Vergote et Frédéric Amant. « Weekly Paclitaxel/Carboplatin in the Treatment of Locally Advanced, Recurrent, or Metastatic Vulvar Cancer ». International Journal of Gynecological Cancer 22, no 5 (juin 2012) : 865–68. http://dx.doi.org/10.1097/igc.0b013e31824b4058.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
4

Raitanen, Misa, Virpi Rantanen, Jarmo Kulmala, Jaakko Pulkkinen, Pekka Klemi, Seija Grénman et Reidar Grénman. « Paclitaxel combined with fractionated radiationin vitro : A study with vulvar squamous cell carcinoma cell lines ». International Journal of Cancer 97, no 6 (8 novembre 2001) : 853–57. http://dx.doi.org/10.1002/ijc.10133.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
5

Denny, Lynette. « International Perspective on the Global Advances in Gynecologic Oncology ». American Society of Clinical Oncology Educational Book, no 32 (juin 2012) : 330–34. http://dx.doi.org/10.14694/edbook_am.2012.32.58.

Texte intégral
Résumé :
Overview: The treatment of gynecologic cancer has evolved over the years, with greater emphasis on tailored surgery and reducing morbidity and mortality related to surgery, particularly in the management of vulvar and cervical cancer. The addition of concurrent chemotherapy to radiation regimens has improved survival of patients with cervical cancer in developed countries; however, most women with cancer in developing countries have advanced, untreatable disease and minimal access to anticancer therapies. In the past 15 years there has been intense research into alternatives to cervical cytologic testing, particularly in low resourced regions but also in an attempt to improve on cytologic testing in developed countries. Surgical staging in endometrial cancer has enabled the use of adjuvant radiation to be individualized to the patient's particular risk factors for recurrence. The management of ovarian cancer, long stagnant since the introduction of platinum and paclitaxel as chemotherapeutic agents, is set to change with the onset of molecular and genetic profiling and the introduction of novel therapies.
Styles APA, Harvard, Vancouver, ISO, etc.
6

Klavans, Madison R., Sarah H. Erickson et Susan C. Modesitt. « Neoadjuvant chemotherapy with paclitaxel/carboplatin/bevacizumab in advanced vulvar cancer : Time to rethink standard of care ? » Gynecologic Oncology Reports 34 (novembre 2020) : 100631. http://dx.doi.org/10.1016/j.gore.2020.100631.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
7

Amant, Frédéric, Linda Nooij, Daniela Annibali, Anne-Sophie van Rompuy, Sileny Han, Heidi van den Bulck et Frédéric Goffin. « Brief Report on 3-Weekly Paclitaxel Carboplatin Efficacy in Locally Advanced or Metastatic Squamous Vulvar Cancer ». Gynecologic and Obstetric Investigation 83, no 6 (2018) : 620–26. http://dx.doi.org/10.1159/000487435.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.
8

Kalpana, B., S. G. Balamurugan et Soumya Ranjan Panda. « Vulval carcinoma at the site of recent Bartholin gland excision : a rare case report ». International Journal of Reproduction, Contraception, Obstetrics and Gynecology 9, no 5 (28 avril 2020) : 2148. http://dx.doi.org/10.18203/2320-1770.ijrcog20201821.

Texte intégral
Résumé :
Around 2-7% of all vulvar cancers are represented by primary carcinomas of Bartholin gland. Here we are presenting such a rare case of carcinoma of Bartholin gland. 45/F P2L2 presented in our OPD with non-healing lesion in vulva for 2 months. She had history of Bartholin’s cyst excision (elsewhere), 2 months back (the exact time since when she is having the non-healing lesion in vulva). Diagnostic biopsy revealed it to be vulval squamous cell carcinoma. She was given two cycles of Neo adjuvant chemotherapy (Inj. Paclitaxel and Carboplatin). In view of better response to the treatment patient was planned for surgery. Patient underwent wide local excision with bilateral inguinofemoral lymphadenectomy. Although the majority of vulvar lesions are benign, especially in women younger than 50 years of age, any solid mass should be carefully evaluated for malignancy. Preferably biopsy of Bartholin gland should be considered if the patient is more than 40 years of age and should be mandatory in a menopausal woman.
Styles APA, Harvard, Vancouver, ISO, etc.
9

Munster, Pamela N., Jasgit C. Sachdev, Gini F. Fleming, Erkut Hasan Borazanci, Jennifer A. Grabowsky, Manish Sharma, Joseph Custodio et al. « Relacorilant (RELA) with nab-paclitaxel (NP) : Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA). » Journal of Clinical Oncology 37, no 15_suppl (20 mai 2019) : 4130. http://dx.doi.org/10.1200/jco.2019.37.15_suppl.4130.

Texte intégral
Résumé :
4130 Background: Glucocorticoid receptor (GR) pathway activation has been linked with chemotherapy resistance (CTR). RELA (formerly CORT125134, Corcept Therapeutics), a potent selective GR modulator, in combination with paclitaxel reduced CTR and enhanced activity against tumor growth in preclinical models of solid tumors. Methods: Patients (pts) with advanced solid tumors, ≤3 prior lines of cytotoxic therapy, ECOG status 0-1, and adequate marrow function received RELA (100, 150, or 200mg) + NP (60, 80, or 100mg/m2). Once daily RELA was given either continuously (CON) or intermittently (INT) (day before, of, and after NP). NP was dosed weekly for 3 of 4 weeks (wks) of a 28-day cycle. Prior NP therapy was allowed. Results: 72 pts have been enrolled [mean age 60 (range 18-81), mean number of prior therapies 3, prior taxane (TXN) treatment 54/72 (75%)]. 61 pts received ≥1 dose of RELA. Grade ≥3 AE ≥10% for CON: neutropenia (6/43, 14%); INT: neutropenia (6/18, 33%), anemia (2/18, 11%), and mucosal inflammation (2/18, 11%). Prophylactic G-CSF became mandatory in later cohorts. Recommended Phase 2 Dose: RELA 100mg-CON/150mg-INT + NP 80mg/m2 (exposures similar to NP 100mg/m2 due to CYP3A4 inhibition by RELA). Disease control (DC) > 24 wks was noted in 5/27 (19%) PDAC pts: 3 PR, 2 SD (27-50 wks). 3 pts achieved benefit despite progression on prior TXN with time to progression (TTP) 1.9-3.6x longer than prior TXN. 4/13 (31%) OvCA pts had DC > 24 wks: 1 CR, 1 PR, 2 SD (33-54+ wks). 1 pt had TTP 4.4x longer than prior TXN. 3 additional PRs were observed: acinar pancreatic cancer, TTP 31 wks (4.4x prior TXN); vulvar SCC HPV+, TTP 55 wks (3.9x prior TXN); cholangiocarcinoma, DC 29+ wks. Expression of GR-regulated genes involved in inflammation, apoptosis, and CTR distinguished pts with DC from pts without DC, providing proof of mechanism. Conclusions: RELA+NP resulted in durable disease control in pts with metastatic PDAC, OvCA, and other solid tumors, including those that have progressed on prior TXN. TTP was often several-fold longer than previously achieved on TXN therapy. Toxicities are manageable with prophylaxis for neutropenia. Further evaluation in OvCA NCT03776812, PDAC, and others are planned. Clinical trial information: NCT02762981.
Styles APA, Harvard, Vancouver, ISO, etc.
10

Witteveen, P. O., J. van der Velden, I. Vergote, C. Guerra, C. Scarabeli, C. Coens, G. Demonty et N. Reed. « Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy : a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group) ». Annals of Oncology 20, no 9 (septembre 2009) : 1511–16. http://dx.doi.org/10.1093/annonc/mdp043.

Texte intégral
Styles APA, Harvard, Vancouver, ISO, etc.

Thèses sur le sujet "Vulvar, cancer, paclitaxel"

1

MALBERTI, SILVIA. « Carcinoma della vulva recidivo dopo chirurgia o localmente avanzato : ruolo e possibilità di chemioterapia neoadiuvante ». Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/28328.

Texte intégral
Résumé :
Background: no standard treatment are avaliable for patients with locally advanced or recurrent vulvar cancer Patients and Methods:35 patients with recurrent and 26 patients with locally advanced vulvar cancer received paclitaxel/cisplatin and or without ifosfamide every 3 weeks for up to 6 cycles. Primary objective was response rate and operability rate. Secondary objective were response duration and toxicity. Response evaluation was assessed by WHO criteria; tossicity according to common toxicity criteria. Results: Sixty-one women were included with a median age of 75 (range 43-85). On study patients receveid a median of 6 cycles. Safety: grade 3 and 4 neutropenia was seen in eleven patients (11/61=18%). Efficay: overall response was 65,3%(17/26; n 17= 2 complete responses+15 partial responses)in patients with locally advanced vulvar cancer.Overall response was 40% (14/35; n 14= 2 complete responses+12 partial responses) in patients with recurrent vulvar cancer. With amedian follow-up of 24 months, median PFS was 13 months in patients with locally advanced vulvar cancer and 9 months in patients with recurrent vulvar cancer. Operability rate was 73% in patients with locally advanced vulvar cancer and 49% in patients with recurrent vulvar cancer Conclusion: this treatment allows moderate control of locally advanced and recurrent vulvar cancer with acceptable side effects
Styles APA, Harvard, Vancouver, ISO, etc.
Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!

Vers la bibliographie